Immuno-Oncology

Immuno-oncology is transforming cancer treatment by harnessing the power of the immune system to identify and eliminate tumors. Leading pharmaceutical and biotech companies are advancing a wide range of innovative approaches across the immuno-oncology landscape. Below are the key areas of focus shaping the future of cancer immunotherapy:

Key Areas:

  • Immune Checkpoint Inhibitors
    Targeting PD-1, PD-L1, CTLA-4, TIGIT, and LAG-3 to overcome immune suppression and reinvigorate T-cell responses.

  • T-Cell Engaging Bispecific Antibodies
    Dual-targeting antibodies that redirect T cells to cancer cells, enabling precise and potent tumor cell killing.

  • CAR-T Cell Therapy
    Genetically engineered T cells that recognize specific cancer antigens, primarily for blood cancers, with ongoing expansion into solid tumors.

  • TCR-T Cell Therapy
    T cells modified with high-affinity T-cell receptors (TCRs) to detect intracellular cancer antigens presented on MHC molecules.

  • Tumor-Infiltrating Lymphocyte (TIL) Therapy
    Expansion of naturally occurring T cells extracted from tumors to enhance the body’s intrinsic antitumor response.

  • Personalized Cancer Vaccines
    mRNA- or peptide-based vaccines tailored to each patient’s unique tumor mutations (neoantigens) to stimulate a targeted immune attack.

  • Oncolytic Viruses
    Engineered viruses that selectively infect and destroy cancer cells while alerting the immune system to tumor presence.

  • Innate Immune Modulation
    Therapies targeting natural killer (NK) cells, dendritic cells, and toll-like receptors (TLRs) to initiate and support adaptive immune responses.

  • Engineered Cytokines
    Modified versions of immune-stimulating proteins like IL-2, IL-15, and IL-12 designed to boost immune activity with fewer side effects.

  • Adenosine Pathway Inhibition
    Blocking immunosuppressive signaling (e.g., via CD73 or A2aR) within the tumor microenvironment to restore immune function.

  • Antibody-Drug Conjugates (ADCs)
    Targeted delivery of cytotoxic agents directly to cancer cells via tumor-specific antibodies, reducing systemic toxicity.

  • Neoantigen & Biomarker-Driven Therapies
    Leveraging genomic profiling and machine learning to identify optimal immunotherapy targets for personalized treatment.

  • Immunotherapy Combinations
    Strategic use of immune agents alongside chemotherapy, radiation, targeted therapies, or other IO drugs to improve efficacy and durability.

  • Off-the-Shelf Allogeneic Cell Therapies
    Scalable, donor-derived T or NK cell products using gene-editing technologies to enable immediate, broad patient access.

  • Others